Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Exclusion Criteria

• •1. Active, known or suspected autoimmune diseases.
• •2. Subjects are being treated with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
• •3. History of severe hypersensitive reactions to other monoclonal antibodies.
• •4. History of allergy or intolerance to study drug components.
• •5. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
• •6. History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function.
• •7. Uncontrolled intercurrent illness, including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
• •8. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
• •9. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.
• •10. Vaccination within 30 days of study enrollment.
• •11. Active bleeding or known hemorrhagic tendency.